The results turned out that among sixty-two NSCLC patients with BRAF V600 mutation, the overall ORR was 37.1% (95% CI, 25.2 to 50.3%), and 37.5% (95% CI, 8.5 to 75.5%) in previously untreated patients, and 37.0% (95% CI, 24.3 to 51.3%) in previously treated patients. This evidence concerns the gene BRAF and non-small cell lung carcinoma.